AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab deruxtecan in July 2020, except ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback